Bob Rosin is the Managing Partner at Antler US, a global early-stage venture capital firm with over $1B in assets under management and investments in more than 1,500 companies. A three-time startup founder who raised over $130M from top investors like Sequoia and Marc Andreessen, he led his third venture, Qik, to a $150M acquisition by Skype, followed by roles as VP of Business Development at Skype and VP & GM at Microsoft after its $8.5B sale. Rosin later drove partnerships at LinkedIn for 4.5 years as part of the product leadership team, headed partnerships at Stripe, served as Partner at Defy.vc from 2020-2025, and joined Antler in 2025 to focus on pre-seed investments, co-founder matching, and scaling ideation-stage startups. He holds an MBA from Harvard Business School and a BA from Cornell University.Topics:

• From repeat founder to investor: lessons from building and exiting multiple startups
• How Antler finds, matches, and backs founders at the idea stage
• What pre-seed investors actually look for before there’s a product or traction

#VentureCapital #PreSeed #StartupFounders #EarlyStageVC #Entrepreneurship

Hemal Shah is a seasoned product leader currently serving as Product lead at OpenAI, where he focuses on integrating ChatGPT into workplace tools like Slack and developing features such as company knowledge powered by GPT-5. Previously, he was VP of Product, Head of Growth, Monetization & Expansion at Atlassian, Chief Product Officer at Root Inc. (NASDAQ: ROOT), and held product roles at Instagram (co-creator of Threads and DMs), Meta (consumer wallet & identity), and Twitter (Developer Tools like Crashlytics).

• From consumer social products to enterprise AI: lessons building at Instagram, Atlassian, and OpenAI
• How ChatGPT is becoming a core workplace tool—and what “AI-native productivity” really means
• Product leadership at scale: monetization, growth, and decision-making inside category-defining companies

#ProductLeadership #AIatWork #OpenAI #EnterpriseAI #TechLeadership

Jim Tananbaum is the founder and CEO of Foresite Capital, a U.S.-focused healthcare investment firm he launched in 2011 that manages approximately $3.5 billion in assets. With a career spanning three decades, Jim has partnered with some of the fastest-growing and most influential healthcare companies of their generation, including 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. A lifelong student of both data science and medicine, his vision for Foresite Capital is to sit at the intersection of biology, technology, and data to support entrepreneurs building transformative healthcare solutions. Earlier in his career, he co-founded GelTex Pharmaceuticals and Theravance, companies that together delivered blockbuster drugs and multibillion-dollar market capitalizations. Jim holds a BS and BSEE from Yale, an MD from Harvard Medical School, and an MBA from Harvard Business School, where he was also part of the Harvard/MIT HST Program.Topics:

• Recent $900M fundraise and bets on Alumis, Latigo Biotherapeutics, Xaira Therapeutics
• 50+ IPOs, 47 public listings, 58 FDA approvals across portfolio
• Foresite Labs incubating ML-powered healthcare startups

#BiotechInvesting #AIBiotech #ForesiteCapital #JimTananbaum #HealthcareInnovation